The U.S. Food and Drug Administration has recently approved the first gene-editing treatment, Casgevy, for sickle cell disease. This one-time treatment, developed by Vertex Pharmaceuticals (NASDAQ: VERX) and CRISPR Therapeutics (NASDAQ: CRSP), utilizes the...